Palatin Technologies, Inc., a biopharmaceutical company, develops targeted, receptor-specific peptide therapeutics for the treatment of various diseases in the United States. The companyÂ’s principal product is Bremelanotide, an as needed subcutaneous injectable peptide melanocortin receptor agonist, which is in the Phase III clinical studies for the treatment of premenopausal women with hypoactive sexual desire disorder (HSDD). Its drug development programs also include Melanocortin receptor-4 (MC4r) peptides and small molecule agonists that are under the preclinical trials for the treatment of conditions responsive to MC4r activation, including female sexual dysfunction, HSDD, erectile dysfunction, obesity, and diabetes; and Melanocortin receptor-1 peptide agonists, which are under preclinical studies for the treatment of inflammatory and dermatologic disease indications, as well as other Melanocortin receptors. In addition, the company is involved in the development of natriuretic peptide receptor-specific programs, including PL-3994, a natriuretic peptide receptor-A, which is in Phase II clinical studies for treatment of heart failure, acute exacerbations of asthma, and refractory hypertension. Palatin Technologies, Inc. was founded in 1986 and is based in Cranbury, New Jersey.
